MARKET ACCESS INTELLIGENCE • Weekly Digest • May 15, 2026

340B Mississippi GOP congressman reverses 340B rebate support after 8 days—the AHA's $72M float critique is changing minds in real time

340B Report broke the story (May 12) that a Mississippi congressman publicly reversed his earlier support for the 340B rebate model just eight days after signing the seven-member House Republican letter backing "timely adoption" of the model. The reversal makes him the first signatory to walk back support, and the timing is striking: it comes immediately after the AHA's April 20 RFI response documented $72 million in average float costs per disproportionate share hospital, $54.2 million in annual float financing under a 4% interest rate assumption, and 30 minutes of manual claim processing time per contested Beacon platform submission. The Mississippi congressman's reversal also coincides with the 5th Circuit's denial of Novartis's rehearing request on Mississippi's contract pharmacy access law—eliminating a major manufacturer legal challenge in the same state. The reversal stands against the broader political math: 94+ bipartisan House members had previously signed the opposing letter to block federal funds for the rebate model, and HRSA's RFI received more than 5,500 comments by the close of the comment period.

Policy PCMA's final "Inside PBM Reform" installment frames CAA 2026 as Medicare affordability opportunity—a strategic pivot toward seniors

PCMA published the final installment of its "Inside PBM Reform" series, focusing explicitly on Medicare beneficiary affordability rather than the more defensive framing used in earlier installments. The blog argues that between the IRA Part D redesign, the CAA 2026 reforms, and ongoing CMS regulations, Medicare's drug benefit is "in constant change" and creates opportunities to improve senior affordability if implemented properly. The piece is the rhetorical bookend to PCMA's April analysis arguing that delink was "Big Pharma's big win," and together they form a coordinated narrative: PBMs as Medicare beneficiary advocates rather than opponents of the reforms they fought during legislation. PCMA CEO David Marin also appeared at the Axios Future of Health Summit this week to deliver the same message in person.

Formulary CMS announces early adopters for electronic prior authorization initiative ahead of 2027 requirements

CMS announced the early adopter cohort for its electronic prior authorization initiative, part of the agency's broader Health Tech Ecosystem framework. Healthcare Dive confirmed the effort aims to accelerate industry progress before electronic PA requirements take effect in 2027 under CMS's interoperability rule. The announcement follows CMS Administrator Oz's earlier blog post calling out PA as an insurer tool for "second-guessing clinicians," and aligns with the KFF analysis documenting growing state-level consumer protections against algorithmic claims denials. The federal initiative creates a counterweight to the patchwork of state-level PA reforms that have proliferated since 2024.

FORMULARY & BIOSIMILARS

• 340B Lilly sends warning letters to providers over in-house 340B claims data reporting (340B Report) — Lilly joins AstraZeneca, AbbVie, UCB, and three others (seven manufacturers total) imposing in-house pharmacy claims data submission requirements on 340B covered entities. The accelerating manufacturer-by-manufacturer attestation regime fragments compliance infrastructure further, requiring covered entities to manage different submission formats, deadlines, and consequences across an increasingly fragmented landscape.
• 340B UCB becomes 7th manufacturer to announce in-house pharmacy claims data requirements; AbbVie updates state restrictions — The pattern is now a clear industry trend: data attestation requirements are becoming a de facto compliance regime for 340B participation. AbbVie's parallel update to which states it considers subject to contract pharmacy restrictions adds another layer of operational complexity for multi-state covered entities tracking manufacturer-by-manufacturer policies.
• Policy Supreme Court preserves mifepristone access while lawsuit continues (STAT News) — The Court rejected lower-court restrictions on the drug, preserving FDA's 2016 and 2021 regulatory changes that expanded telehealth and mail-order access. For market access teams, the ruling sets precedent on judicial deference to FDA regulatory decisions that could affect future challenges to drug approvals and REMS modifications.

PRICING & REIMBURSEMENT

• Pricing Evernorth survey: 90%+ of employers prefer rebate-free PBM models (Healthcare Dive) — The Penta Group survey commissioned by Evernorth (Cigna's PBM parent for Express Scripts) found more than 90% of employers agreed that rebate-free approaches are easier to understand and would improve transparency. Significant because Evernorth itself commissioned the survey—the company that operates a rebate-driven PBM is documenting that employer customers prefer the model PBMs spent years opposing.
• Pricing Drug Channels: Single-channel ecosystems to protect gross-to-net — PHIL Inc.'s guest post argues that growing pricing pressure is exposing structural inefficiencies in GTN management across traditional channels, and that single-channel ecosystems (one vertically integrated dispensing/coverage/affordability solution per drug) can better coordinate the moving parts. This is the next-generation manufacturer commercial platform thesis Drug Channels has been building since the CVS/Cordavis and Amazon/Cost Plus DTC analyses.
• Pricing Drug Channels mid-May roundup: launch pricing math, pharmacy closures, 340B hospitals vs. grantees — DCI's Bryce Platt covers five themes: flawed launch price math in industry analyses, accelerating retail pharmacy closures driven by reimbursement compression, hospital staff compensation realities, the growing divergence between 340B hospital interests and grantee/FQHC interests, and an emerging luxury specialty pharmacy market. The 340B intra-program divergence is the most strategically significant—Bergman-Auchincloss bill exemptions explicitly target this divide.

POLICY & REGULATORY

• 340B 5th Circuit denies Novartis rehearing on Mississippi 340B contract pharmacy law — Eliminates a major appellate challenge to Mississippi's law, solidifying the 5th Circuit's position upholding state contract pharmacy protections. With the 4th Circuit going the opposite direction on Maryland and West Virginia, the circuit split now appears permanent and Supreme Court certiorari becomes the only remaining path to national resolution.
• 340B Senate 340B critic faces tough Saturday GOP primary in Louisiana (340B Report) — A high-ranking senator who has been a vocal 340B critic faces a competitive GOP primary Saturday against two challengers. A loss would remove one of the program's most influential Congressional critics; a win would consolidate his position as a leading 340B reform advocate. The Louisiana primary outcome will signal whether the Senate's 340B reform energy carries into 2027.
• Policy Bipartisan lawmakers reintroduce bill barring PBMs from owning pharmacies (Fierce Healthcare) — The reintroduction targets the vertical integration that has driven Big Three PBM growth: CVS Caremark/CVS Pharmacy, Express Scripts/Accredo, OptumRx/Optum Specialty. If enacted, it would force structural separation that would unwind a decade of consolidation. Bipartisan reintroduction signals genuine legislative viability even if the bill doesn't pass this Congress.
• Policy PCMA CEO David Marin at Axios Future of Health Summit — Marin's appearance reinforces PCMA's strategic pivot to public advocacy framing rather than defensive lobbying. With CAA 2026 enacted, PCMA is repositioning PBMs as transparency champions and Medicare affordability allies—a complete reversal of the industry's pre-2025 posture.

WHAT TO WATCH NEXT

Remaining six 340B rebate letter signatories—more reversals coming?

The Mississippi congressman's reversal makes him the first of seven GOP signatories to walk back the rebate model letter within eight days. Hospital associations in the remaining six lawmakers' districts have now seen the AHA's $72M float critique gain traction—and have a tested playbook for engaging their representatives. Watch for additional reversals over the next two weeks. Each one further narrows the political path to a HRSA rebate model implementation.

Lilly warning letters and the in-house pharmacy data attestation regime

Lilly's warning letters to providers over in-house 340B claims data reporting bring the total to seven manufacturers (joining AstraZeneca, AbbVie, UCB, and three others) requiring direct data submissions. The attestation regime is becoming the de facto compliance infrastructure for 340B—but each manufacturer's requirements differ, creating cumulative operational burden. Watch for covered entity coalitions to push for a single neutral claims clearinghouse, similar to the framework being developed by emerging vendors.

Louisiana Saturday GOP primary—Senate 340B reform trajectory

Saturday's primary outcome shapes Senate HELP's 340B reform trajectory. A loss for the incumbent 340B critic removes one of the most active Congressional reform voices. A narrow win signals that even prominent 340B reform advocates face base-voter pressure on other issues, potentially making 340B reform a lower legislative priority through 2027.